DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Jaeryung | ko |
dc.contributor.author | Kim, Tae Eun | ko |
dc.contributor.author | Kim, Ju-A | ko |
dc.contributor.author | Yun, Ji-Hyun | ko |
dc.contributor.author | Sohn, Seongsoo | ko |
dc.contributor.author | Shim, Sang Ryeol | ko |
dc.contributor.author | Lee, Sang Hoon | ko |
dc.contributor.author | Kim, Sang Jin | ko |
dc.date.accessioned | 2015-11-20T09:50:24Z | - |
dc.date.available | 2015-11-20T09:50:24Z | - |
dc.date.created | 2014-12-29 | - |
dc.date.created | 2014-12-29 | - |
dc.date.issued | 2014-12 | - |
dc.identifier.citation | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, v.30, no.10, pp.847 - 853 | - |
dc.identifier.issn | 1080-7683 | - |
dc.identifier.uri | http://hdl.handle.net/10203/201110 | - |
dc.description.abstract | Purpose: The study investigated the effect of intravitreally administered tanibirumab, a fully human monoclonal antibody against vascular endothelial growth factor receptor 2, in a rat model of laser-induced choroidal neovascularization (CNV). Methods: CNV was induced by laser photocoagulation on day 0 in the eyes of Brown Norway rats. Intravitreal injection of tanibirumab or phosphate-buffered saline (PBS) was done on day 0 (prevention arm) or day 7 (treatment arm). Seven days after injection, the eyes were enucleated and retinal pigment epithelium-choroid-sclera flat mounts were prepared. Areas of CNV were determined in the flat mounts using tetramethylrhodamine isothiocyanate Bandeiraea simplicifolia (BS) isolectin labeling and intravenously administered fluorescein isothiocyanate-dextran and quantified using an image analysis program. Results: In the prevention arm, the mean area of CNV measured by BS isolectin labeling was reduced by 28.2% and 53.9% in tanibirumab-treated eyes (20 and 60 mu g, respectively) compared with PBS-treated control eyes on day 7 (P=0.038 and P<0.001, respectively). In the treatment arm, the mean area of CNV measured by BS isolectin labeling was reduced by 28.7% and 46.0% in tanibirumab-treated eyes (20 and 60 mu g, respectively) compared with PBS-treated control eyes on day 14 (P=0.048 and P<0.001, respectively). Conclusions: Intravitreally administered tanibirumab partially suppressed the formation of new CNV and partially regressed preformed laser-induced CNV in the rat model. Tanibirumab may be a feasible treatment for CNV associated with age-related macular degeneration or other causes. | - |
dc.language | English | - |
dc.publisher | MARY ANN LIEBERT, INC | - |
dc.subject | MACULAR DEGENERATION | - |
dc.subject | TYROSINE KINASE | - |
dc.subject | IN-VITRO | - |
dc.subject | VEGF-A | - |
dc.subject | INHIBITOR | - |
dc.subject | CANCER | - |
dc.subject | BEVACIZUMAB | - |
dc.subject | THERAPY | - |
dc.subject | DISEASE | - |
dc.subject | RETINA | - |
dc.title | Intravitreal Tanibirumab, a Fully Human Monoclonal Antibody Against Vascular Endothelial Growth Factor Receptor 2, Partially Suppresses and Regresses Laser-Induced Choroidal Neovascularization in a Rat Model | - |
dc.type | Article | - |
dc.identifier.wosid | 000345684400010 | - |
dc.identifier.scopusid | 2-s2.0-84915775917 | - |
dc.type.rims | ART | - |
dc.citation.volume | 30 | - |
dc.citation.issue | 10 | - |
dc.citation.beginningpage | 847 | - |
dc.citation.endingpage | 853 | - |
dc.citation.publicationname | JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS | - |
dc.identifier.doi | 10.1089/jop.2014.0021 | - |
dc.contributor.nonIdAuthor | Kim, Tae Eun | - |
dc.contributor.nonIdAuthor | Kim, Ju-A | - |
dc.contributor.nonIdAuthor | Yun, Ji-Hyun | - |
dc.contributor.nonIdAuthor | Sohn, Seongsoo | - |
dc.contributor.nonIdAuthor | Shim, Sang Ryeol | - |
dc.contributor.nonIdAuthor | Lee, Sang Hoon | - |
dc.contributor.nonIdAuthor | Kim, Sang Jin | - |
dc.type.journalArticle | Article | - |
dc.subject.keywordPlus | MACULAR DEGENERATION | - |
dc.subject.keywordPlus | TYROSINE KINASE | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | VEGF-A | - |
dc.subject.keywordPlus | INHIBITOR | - |
dc.subject.keywordPlus | CANCER | - |
dc.subject.keywordPlus | BEVACIZUMAB | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | DISEASE | - |
dc.subject.keywordPlus | RETINA | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.